These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23346484)

  • 21. Triglycerides/high-density lipoprotein cholesterol is a predictor similar to the triglyceride-glucose index for the diagnosis of metabolic syndrome using International Diabetes Federation criteria of insulin resistance in obese adolescents: a cross-sectional study.
    Aslan Çin NN; Yardımcı H; Koç N; Uçaktürk SA; Akçil Ok M
    J Pediatr Endocrinol Metab; 2020 May; 33(6):777-784. PubMed ID: 32447329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary metabolomics predict the severity of overactive bladder syndrome in an aging female population.
    Mossa AH; Shamout S; Cammisotto P; Campeau L
    Int Urogynecol J; 2020 May; 31(5):1023-1031. PubMed ID: 31813035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fasting plasma glucose is a stronger predictor of diabetes than triglyceride-glucose index, triglycerides/high-density lipoprotein cholesterol, and homeostasis model assessment of insulin resistance: Tehran Lipid and Glucose Study.
    Tohidi M; Baghbani-Oskouei A; Ahanchi NS; Azizi F; Hadaegh F
    Acta Diabetol; 2018 Oct; 55(10):1067-1074. PubMed ID: 30066042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between neck circumference and overactive bladder in women with metabolic syndrome: a preliminary study.
    Akin Y; Gulmez H; Savas M; Aykan S; Onder O; Yucel S
    Wien Klin Wochenschr; 2016 Dec; 128(Suppl 8):581-586. PubMed ID: 25854906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of bladder wall thickness in women with overactive bladder.
    Üçer O; Gümüş B; Albaz AC; Pekindil G
    Turk J Urol; 2016 Jun; 42(2):97-100. PubMed ID: 27274895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.
    Arlandis S; Ruiz MA; Errando C; Villacampa F; Arumí D; Lizarraga I; Rejas J
    Clin Drug Investig; 2012 Aug; 32(8):523-32. PubMed ID: 22741748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are patients with the symptoms of overactive bladder and urodynamic detrusor overactivity different from those with overactive bladder but not detrusor overactivity?
    Fan YH; Lin CC; Lin AT; Chen KK
    J Chin Med Assoc; 2011 Oct; 74(10):455-9. PubMed ID: 22036137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the Arabic linguistic version of the Overactive Bladder Symptoms Score questionnaire.
    Elbaset MA; Hashem A; Taha DE; Zahran MH; El-Hefnawy AS
    Arab J Urol; 2019; 17(4):265-269. PubMed ID: 31723443
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients.
    Taniguchi A; Fukushima M; Sakai M; Kataoka K; Nagata I; Doi K; Arakawa H; Nagasaka S; Tokuyama K; Nakai Y
    Metabolism; 2000 Aug; 49(8):1001-5. PubMed ID: 10954017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
    Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
    Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease.
    Oh SY; Cho YK; Kang MS; Yoo TW; Park JH; Kim HJ; Park DI; Sohn CI; Jeon WK; Kim BI; Son BH; Shin JH
    Metabolism; 2006 Dec; 55(12):1604-9. PubMed ID: 17142131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population.
    Lai HH; Shen B; Rawal A; Vetter J
    BMC Urol; 2016 Oct; 16(1):60. PubMed ID: 27716241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sleep Disturbance and Fatigue Are Associated With More Severe Urinary Incontinence and Overactive Bladder Symptoms.
    Ge TJ; Vetter J; Lai HH
    Urology; 2017 Nov; 109():67-73. PubMed ID: 28826875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations Between Serum Uric Acid Concentrations and Cardiometabolic Risk and Renal Injury in Obese and Overweight Children.
    Özalp Kızılay D; Şen S; Ersoy B
    J Clin Res Pediatr Endocrinol; 2019 Sep; 11(3):262-269. PubMed ID: 30759960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.
    Villacampa F; Ruiz MA; Errando C; Arlandis S; Arumí D; Lizarraga I; Rejas J
    Int Urogynecol J; 2013 Apr; 24(4):573-81. PubMed ID: 23111865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women.
    Kheirollahi A; Teimouri M; Karimi M; Vatannejad A; Moradi N; Borumandnia N; Sadeghi A
    Lipids Health Dis; 2020 Nov; 19(1):235. PubMed ID: 33161896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is overactive bladder microvasculature disease a component of systemic atheroscleorosis?
    Yeniel AO; Ergenoglu AM; Meseri R; Kismali E; Ari A; Kavukcu G; Aydin HH; Ak H; Atay S; Itil IM
    Neurourol Urodyn; 2018 Apr; 37(4):1372-1379. PubMed ID: 29140571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.